Becton Dickinson & Financial Results
Becton, Dickinson and Company (BD) reported Q4 fiscal 2026 revenue of $5.3 billion, a 5.4% increase, and full-year revenue of $19.5 billion. The company highlighted the completion of its transformation into a more focused MedTech company following the separation of its Life Sciences business and issued guidance for fiscal 2027.
“We delivered a strong fourth quarter, with 5.6% revenue growth and broad-based performance led by our key growth platforms. Fiscal 2026 was a defining year as we completed BD's transformation to a more focused MedTech company with separation of our Life Sciences business. We strengthened our core growth and expanded BD Excellence to elevate our commercial capabilities, accelerate innovation and drive greater productivity. We enter fiscal 2027 from a position of strength, with a portfolio built for durable performance and confidence in the long-term growth, earnings and cash-flow potential of New BD.”
Tom Polen, chairman, CEO and president of BD